Cullinan Therapeutics Q3 net loss narrows to $49.4 million
CGEM•Cullinan Therapeutics’ third-quarter 2026 net loss narrowed year over year to $49.4 million. Cash and investments totaled $313.8 million at September 30, with resources expected to fund operations into 2029.
1. Quarterly results and updates
Cullinan Therapeutics reported a third-quarter 2026 net loss of $49.4 million, narrowed year over year. General and administrative expenses fell 9% to $12.4 million, and research and development spending declined to $40.2 million. Taiho initiated the NDA submission for zipalertinib’s first-line combination therapy, with completion expected in November. The company plans to share CLN-978 multi-dose data across three autoimmune indications in December.
